
Opinion|Videos|April 22, 2026
What the introduction of bispecific antibodies has meant for the treatment of multiple myeloma
Author(s)C. Brooke Adams, Pharm.D., BCOP
Bispecific antibodies are highly efficacious and have a milder side effect profile than other late-line treatments for multiple myeloma, according to Adams.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves Simtriyo, the first triple reuptake inhibitor for ADHD
2
Head-to-head study shows Dovato as effective as Biktarvy in HIV | AIDS 2026
3
Healthcare’s next challenge isn’t technology. It’s alignment
4
Is 340B good for the healthcare system? Takeaways from an MHE/Drug Topics webinar
5
























